Search Results

FH1 25 mg  | 99.95%

TargetMol

FH1 (BRD-K4477), a small molecule, enhances the functions of hepatocytes and promotes differentiation hepatocytes derived by iPS.

More Information Supplier Page

FH1 10 mg  | 99.95%

TargetMol

FH1 (BRD-K4477), a small molecule, enhances the functions of hepatocytes and promotes differentiation hepatocytes derived by iPS.

More Information Supplier Page

Navitoclax 50 mg  | 98.88%

TargetMol

Navitoclax (ABT-263) is a potent, orally bioavailable Bcl-2 family protein inhibitor that avidly binds Bcl-2, Bcl-xL, and Bcl-W (Ki < 1 nM for all three proteins).

More Information Supplier Page

Navitoclax 25 mg  | 98.88%

TargetMol

Navitoclax (ABT-263) is a potent, orally bioavailable Bcl-2 family protein inhibitor that avidly binds Bcl-2, Bcl-xL, and Bcl-W (Ki < 1 nM for all three proteins).

More Information Supplier Page

Navitoclax 10 mg  | 98.88%

TargetMol

Navitoclax (ABT-263) is a potent, orally bioavailable Bcl-2 family protein inhibitor that avidly binds Bcl-2, Bcl-xL, and Bcl-W (Ki < 1 nM for all three proteins).

More Information Supplier Page

FH1 50 mg  | 99.95%

TargetMol

FH1 (BRD-K4477), a small molecule, enhances the functions of hepatocytes and promotes differentiation hepatocytes derived by iPS.

More Information Supplier Page

AEE788 5 mg  | Purity Not Available

TargetMol

AEE788 has been used in trials studying the treatment of Cancer, Glioblastoma Multiforme, and Brain and Central Nervous System Tumors.

More Information Supplier Page